Clinical Trials Directory

Trials / Unknown

UnknownNCT05780450

Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.

Effectiveness of Transcranial Direct Current (tDCS) Treatment in Patients With Persistent Covid Who Present Headaches and Chronic Body Pain.

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
27 (estimated)
Sponsor
Fundación Universidad Católica de Valencia San Vicente Mártir · Academic / Other
Sex
All
Age
16 Years
Healthy volunteers
Not accepted

Summary

This study aims to verify the efficacy / effectiveness of treatment with transcranial direct therapy (TDCS) in patients with Persistent Covid who present headaches, migraines and chronic pain, such as arthralgias and myalgias. Transcranial Direct Therapy is used in the field of Physiotherapy and Rehabilitation, with results that prove to be effective for the treatment of patients suffering from symptoms such as migraines, headaches, chronic pain, fibromyalgia or chronic neuropathic pain. As can be seen, in the case of patients with Persistent Covid we find several of these symptoms, so it is suggested that, if Transcranial Direct Current Therapy (TDCs) is giving such good results, relieving these symptoms, why can not give such good results and help so much in patients with Persistent Covid, If many of the symptoms are the same, even if the origin or cause is different.

Conditions

Interventions

TypeNameDescription
DEVICETranscranial Direct Current Therapy (tDCS)Transcranial direct therapy (tDCS) is a non-invasive neuromodulation therapy of the cerebral cortex, which consists of the application of electrical microcurrents, of approximately 2mA, through surface electrodes placed on the scalp. Transcranial therapy (tDCS) produces immediate effects on the ability of neurons to change their electrical potential. Each session lasts between 20 and 30 minutes, and approximately 10 consecutive sessions should be performed. It will be applied through two surface electrodes of 25 to 35 cm2 at 2 mA. The equipment has a European health certificate (CE), so it is an approved equipment that complies with all the safety measures for the application of the treatment.

Timeline

Start date
2023-04-01
Primary completion
2023-07-01
Completion
2023-07-01
First posted
2023-03-22
Last updated
2023-06-13

Locations

2 sites across 1 country: Spain

Source: ClinicalTrials.gov record NCT05780450. Inclusion in this directory is not an endorsement.